{"success":true,"data":{"pressRelease":{"id":"161895","rtpr_id":"nGNXcKcxJ-20261006","ticker":"QXL","exchange":"NASDAQ","all_tickers":["QXL"],"title":"QuantumXLabs Reports Approximately 16.8x Acceleration Over CPU-Based Computing in Quantum-Enabled Analysis of More Than 7 Billion Gene Combinations Using Real-World Clinical Data","author":"Globe Newswire","published_at":"2026-10-06T12:55:00.123Z","article_body":"The demonstration represents another development milestone in the Company’s\ndevelopment of quantum-enabled platform for high-dimensional clinical data\nanalysis \n\nTel Aviv, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Quantum X Labs Inc.\n(Nasdaq: QXL) (“Quantum X” or the “Company”), an advanced technologies\ncompany, today reported its GPU-accelerated quantum-simulation platform\nachieved an approximately 16.8-fold computational acceleration using a single\nmachine with 64 cores (x86_64) and a single NVIDIA T4 Tensor Core GPU compared\nwith the same 64-vCPU machine with only CPU implementation.\n\nThe evaluation used a real clinical gene-expression dataset comprising 11\npatients and 3,531 gene-expression features, representing a challenging\nhigh-dimensional setting in which the number of biological variables greatly\nexceeds the number of patients.\n\nQuantum X’s proprietary algorithm, operated through its subsidiary\nCliniQuantum, searched for correlated three-gene configurations across the\ndataset. The 3,531 genes generated 7,331,162,245 possible three-gene\ncombinations. Using a predefined minimum correlation threshold, the algorithm\nidentified approximately 22.2 million correlated gene triplets.\n\nThe analysis required approximately 8.4 hours using 64 vCPUs, compared with\napproximately 0.5 hours when accelerated using a single NVIDIA T4 GPU, while\nproducing the same qualifying gene-triplet results.\n\n“This represents an important development milestone for Quantum X Labs,”\nsaid Dr. Tidhar Turgeman, head of clinical trials data analysis. “Clinical\nand molecular datasets can contain thousands of variables but relatively few\npatients, creating enormous combinatorial search spaces. Demonstrating the\nability to evaluate more than 7.3 billion potential gene combinations on real\nclinical data marks an important step in our development. The significant GPU\nacceleration further supports our continuing development of scalable,\nquantum-enabled approaches for biomarker discovery and patient\nstratification.”\n\nThe benchmark was conducted on an AWS g4dn.16xlarge EC2 machine using IBM\nQiskit Aer GPU-based quantum simulation, with an NVIDIA T4 Tensor Core GPU.\nThe benchmark was designed to evaluate computational performance and did not\nevaluate or establish the clinical validity, predictive value, or potential\nutility of any identified gene combinations.\n\nQuantumXLabs intends to continue advancing its algorithms toward the analysis\nof increasingly complex multi-feature configurations and larger biomedical\ndatasets, while progressing its development pathway from simulation and\nvalidation toward execution on quantum computing hardware.\n\nQuantum X Labs Inc.\n\nQuantum X Labs Inc. and its subsidiaries are focused on quantum technology,\ndigital advertising and computing and enterprise artificial intelligence (AI)\nsolutions. Quantum X Labs Ltd. is focused on developing and promoting quantum\nalgorithms for the transportation, drug discovery and security segments as\nwell as developing quantum- based GPS replacement and quantum atom accuracy\nsolutions. Gix Media develops a variety of technological software solutions,\nwhich perform automation, optimization and monetization of internet campaigns,\nfor the purposes of acquiring and routing internet user traffic to its\ncustomers. Metagramm is a developer of grammatical error correction software\nand offers tools for writing and reviewing, grammar, spelling, punctuation and\nstyle features, as well as translation and multilingual dictionaries, using\nartificial intelligence and machine learning technology.\n\nFor more information about Quantum X Labs, visit https://quantumxlabs.xyz/\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe “safe harbor” provisions of the Private Securities Litigation Reform\nAct of 1995 and other Federal securities laws. Forward-looking statements\ncontained in this press release include, but are not limited to, statements\nregarding Quantum X Labs’ and its subsidiaries’ strategic and business\nplans, technology, relationships, objectives and expectations for its\nbusiness, growth, the impact of trends on and interest in its business,\nintellectual property, products and its future results, operations and\nfinancial performance and condition and may be identified by the use of words\nsuch as “may,” “seek,” “will,” “consider,” “likely,”\n“assume,” “estimate,” “expect,” “anticipate,” “intend,”\n“believe,” “do not believe,” “aim,” “predict,” “plan,”\n“project,” “continue,” “potential,” “guidance,”\n“objective,” “outlook,” “trends,” “future,” “could,”\n“would,” “should,” “target,” “on track” or their negatives or\nvariations, and similar terminology and words of similar import, generally\ninvolve future or forward-looking statements. For example, the Company is\nusing forward-looking statements when it discusses the continued development\nand optimization of its technologies, the expansion of its research and\ndevelopment activities, potential applications of its solutions, the\nadvancement of its business strategy, and its expectations regarding future\nperformance and growth opportunities. Forward-looking statements are not\nhistorical facts, and are based upon management’s current expectations,\nbeliefs and projections, many of which, by their nature, are inherently\nuncertain. Such expectations, beliefs and projections are expressed in good\nfaith. However, there can be no assurance that management’s expectations,\nbeliefs and projections will be achieved, and actual results may differ\nmaterially from what is expressed in or indicated by the forward-looking\nstatements. Forward-looking statements are subject to risks and uncertainties\nthat could cause actual performance or results to differ materially from those\nexpressed in the forward-looking statements. For a more detailed description\nof the risks and uncertainties affecting the Company, reference is made to the\nCompany’s reports filed from time to time with the Securities and Exchange\nCommission (“SEC”), including, but not limited to, the risks detailed in\nthe Company’s most recent Annual Report on 10-K and in subsequent filings\nwith the SEC. Forward-looking statements speak only as of the date the\nstatements are made. The Company assumes no obligation to update\nforward-looking statements to reflect actual results, subsequent events or\ncircumstances, changes in assumptions or changes in other factors affecting\nforward-looking information except to the extent required by applicable\nsecurities laws. If the Company does update one or more forward-looking\nstatements, no inference should be drawn that the Company will make additional\nupdates with respect thereto or with respect to other forward-looking\nstatements. References and links to websites have been provided as a\nconvenience, and the information contained on such websites is not\nincorporated by reference into this press release. Quantum X Labs is not\nresponsible for the content of third-party websites. \n\nInvestor Relations Contacts:\n\nMichal Efraty\nInvestor Relations\nmichal@efraty.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/a0abc50a-ff3e-420e-9e21-807bbc6417cd)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXcKcxJ-20261006","title":"QuantumXLabs Reports Approximately 16.8x Acceleration Over CPU-Based Computing in Quantum-Enabled Analysis of More Than 7 Billion Gene Combinations Using Real-World Clinical Data","author":"Globe Newswire","ticker":"QXL","created":"2026-10-06T12:55:00.123Z","tickers":["QXL"],"exchange":"NASDAQ","article_body":"The demonstration represents another development milestone in the Company’s\ndevelopment of quantum-enabled platform for high-dimensional clinical data\nanalysis \n\nTel Aviv, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Quantum X Labs Inc.\n(Nasdaq: QXL) (“Quantum X” or the “Company”), an advanced technologies\ncompany, today reported its GPU-accelerated quantum-simulation platform\nachieved an approximately 16.8-fold computational acceleration using a single\nmachine with 64 cores (x86_64) and a single NVIDIA T4 Tensor Core GPU compared\nwith the same 64-vCPU machine with only CPU implementation.\n\nThe evaluation used a real clinical gene-expression dataset comprising 11\npatients and 3,531 gene-expression features, representing a challenging\nhigh-dimensional setting in which the number of biological variables greatly\nexceeds the number of patients.\n\nQuantum X’s proprietary algorithm, operated through its subsidiary\nCliniQuantum, searched for correlated three-gene configurations across the\ndataset. The 3,531 genes generated 7,331,162,245 possible three-gene\ncombinations. Using a predefined minimum correlation threshold, the algorithm\nidentified approximately 22.2 million correlated gene triplets.\n\nThe analysis required approximately 8.4 hours using 64 vCPUs, compared with\napproximately 0.5 hours when accelerated using a single NVIDIA T4 GPU, while\nproducing the same qualifying gene-triplet results.\n\n“This represents an important development milestone for Quantum X Labs,”\nsaid Dr. Tidhar Turgeman, head of clinical trials data analysis. “Clinical\nand molecular datasets can contain thousands of variables but relatively few\npatients, creating enormous combinatorial search spaces. Demonstrating the\nability to evaluate more than 7.3 billion potential gene combinations on real\nclinical data marks an important step in our development. The significant GPU\nacceleration further supports our continuing development of scalable,\nquantum-enabled approaches for biomarker discovery and patient\nstratification.”\n\nThe benchmark was conducted on an AWS g4dn.16xlarge EC2 machine using IBM\nQiskit Aer GPU-based quantum simulation, with an NVIDIA T4 Tensor Core GPU.\nThe benchmark was designed to evaluate computational performance and did not\nevaluate or establish the clinical validity, predictive value, or potential\nutility of any identified gene combinations.\n\nQuantumXLabs intends to continue advancing its algorithms toward the analysis\nof increasingly complex multi-feature configurations and larger biomedical\ndatasets, while progressing its development pathway from simulation and\nvalidation toward execution on quantum computing hardware.\n\nQuantum X Labs Inc.\n\nQuantum X Labs Inc. and its subsidiaries are focused on quantum technology,\ndigital advertising and computing and enterprise artificial intelligence (AI)\nsolutions. Quantum X Labs Ltd. is focused on developing and promoting quantum\nalgorithms for the transportation, drug discovery and security segments as\nwell as developing quantum- based GPS replacement and quantum atom accuracy\nsolutions. Gix Media develops a variety of technological software solutions,\nwhich perform automation, optimization and monetization of internet campaigns,\nfor the purposes of acquiring and routing internet user traffic to its\ncustomers. Metagramm is a developer of grammatical error correction software\nand offers tools for writing and reviewing, grammar, spelling, punctuation and\nstyle features, as well as translation and multilingual dictionaries, using\nartificial intelligence and machine learning technology.\n\nFor more information about Quantum X Labs, visit https://quantumxlabs.xyz/\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe “safe harbor” provisions of the Private Securities Litigation Reform\nAct of 1995 and other Federal securities laws. Forward-looking statements\ncontained in this press release include, but are not limited to, statements\nregarding Quantum X Labs’ and its subsidiaries’ strategic and business\nplans, technology, relationships, objectives and expectations for its\nbusiness, growth, the impact of trends on and interest in its business,\nintellectual property, products and its future results, operations and\nfinancial performance and condition and may be identified by the use of words\nsuch as “may,” “seek,” “will,” “consider,” “likely,”\n“assume,” “estimate,” “expect,” “anticipate,” “intend,”\n“believe,” “do not believe,” “aim,” “predict,” “plan,”\n“project,” “continue,” “potential,” “guidance,”\n“objective,” “outlook,” “trends,” “future,” “could,”\n“would,” “should,” “target,” “on track” or their negatives or\nvariations, and similar terminology and words of similar import, generally\ninvolve future or forward-looking statements. For example, the Company is\nusing forward-looking statements when it discusses the continued development\nand optimization of its technologies, the expansion of its research and\ndevelopment activities, potential applications of its solutions, the\nadvancement of its business strategy, and its expectations regarding future\nperformance and growth opportunities. Forward-looking statements are not\nhistorical facts, and are based upon management’s current expectations,\nbeliefs and projections, many of which, by their nature, are inherently\nuncertain. Such expectations, beliefs and projections are expressed in good\nfaith. However, there can be no assurance that management’s expectations,\nbeliefs and projections will be achieved, and actual results may differ\nmaterially from what is expressed in or indicated by the forward-looking\nstatements. Forward-looking statements are subject to risks and uncertainties\nthat could cause actual performance or results to differ materially from those\nexpressed in the forward-looking statements. For a more detailed description\nof the risks and uncertainties affecting the Company, reference is made to the\nCompany’s reports filed from time to time with the Securities and Exchange\nCommission (“SEC”), including, but not limited to, the risks detailed in\nthe Company’s most recent Annual Report on 10-K and in subsequent filings\nwith the SEC. Forward-looking statements speak only as of the date the\nstatements are made. The Company assumes no obligation to update\nforward-looking statements to reflect actual results, subsequent events or\ncircumstances, changes in assumptions or changes in other factors affecting\nforward-looking information except to the extent required by applicable\nsecurities laws. If the Company does update one or more forward-looking\nstatements, no inference should be drawn that the Company will make additional\nupdates with respect thereto or with respect to other forward-looking\nstatements. References and links to websites have been provided as a\nconvenience, and the information contained on such websites is not\nincorporated by reference into this press release. Quantum X Labs is not\nresponsible for the content of third-party websites. \n\nInvestor Relations Contacts:\n\nMichal Efraty\nInvestor Relations\nmichal@efraty.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/a0abc50a-ff3e-420e-9e21-807bbc6417cd)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-06T12:55:00.168148075Z","server_sent_at_ms":1791291300168},"received_at":"2026-10-06T12:55:00.300Z","source_url":null},"analysis":{"id":"150401","press_release_id":"161895","analysis_json":{"industry":{"label":"Software","sector":"Information Technology"},"redFlags":["Benchmark based on only 11 patients and 3,531 gene features — very small dataset","Release explicitly disclaims clinical validity, predictive value, or utility of identified gene combinations","Promotional 'milestone' release from a small-cap multi-segment holding-style technology company with no revenue or commercial metrics disclosed"],"eventType":"operations_update","narrative":"Quantum X Labs reported its GPU-accelerated quantum-simulation platform achieved roughly a 16.8x speedup over a CPU-only implementation, analyzing more than 7.3 billion possible three-gene combinations on real clinical gene-expression data.\n\nThe benchmark ran on an AWS g4dn.16xlarge instance with a single NVIDIA T4 GPU and IBM Qiskit Aer, cutting analysis time from about 8.4 hours to about 0.5 hours while producing the same ~22.2 million correlated gene triplets.\n\nThe company cautioned the benchmark evaluated computational performance only and did not establish clinical validity or predictive value of any gene combinations; Quantum X plans to progress toward larger datasets and eventual execution on quantum hardware.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Technical benchmark milestone with explicit clinical-validity disclaimer — interesting for quantum/bioinformatics watchers but not investment-relevant yet."},"keyFigures":{"customDimensions":{"benchmark_hardware":"AWS g4dn.16xlarge with NVIDIA T4 Tensor Core GPU, IBM Qiskit Aer simulation","cpu_analysis_hours":"~8.4","gpu_analysis_hours":"~0.5","patients_in_dataset":11,"gpu_acceleration_factor":"~16.8x","gene_expression_features":3531,"three_gene_combinations_searched":7331162245,"correlated_gene_triplets_identified":"~22.2 million"}},"quotedText":"Demonstrating the ability to evaluate more than 7.3 billion potential gene combinations on real clinical data marks an important step in our development.","namedEntities":{"people":[{"name":"Dr. Tidhar Turgeman","role":"Head of clinical trials data analysis"},{"name":"Michal Efraty","role":"Investor Relations"}],"products":["GPU-accelerated quantum-simulation platform","CliniQuantum","NVIDIA T4 Tensor Core GPU","IBM Qiskit Aer"],"companies":[{"name":"Quantum X Labs Inc.","ticker":"QXL","relationship":"filer"},{"name":"CliniQuantum","relationship":"subsidiary"},{"name":"Gix Media","relationship":"subsidiary"},{"name":"Metagramm","relationship":"subsidiary"},{"name":"NVIDIA","ticker":"NVDA","relationship":"hardware supplier"},{"name":"Amazon Web Services","relationship":"cloud infrastructure provider"},{"name":"IBM","ticker":"IBM","relationship":"quantum simulation software (Qiskit Aer)"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"A technology development milestone: ~16.8x GPU acceleration on a benchmark of only 11 patients / 3,531 genes. The release explicitly disclaims clinical validity, so it is a promotional development update, not a market-moving event."},"tickerRelevance":{"others":[{"ticker":"NVDA","relevance":"hardware supplier (GPU used in benchmark)"},{"ticker":"IBM","relevance":"software provider (Qiskit Aer simulation)"}],"primary":"QXL"},"globalImportance":15,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"technical benchmark, no commercial impact","issuerAuthored":true,"clinicalValidityDisclaimed":true}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Quantum X Labs reported its GPU-accelerated quantum-simulation platform achieved roughly a 16.8x speedup over a CPU-only implementation, analyzing more than 7.3 billion possible three-gene combinations on real clinical gene-expression data.\n\nThe benchmark ran on an AWS g4dn.16xlarge instance with a single NVIDIA T4 GPU and IBM Qiskit Aer, cutting analysis time from about 8.4 hours to about 0.5 hours while producing the same ~22.2 million correlated gene triplets.\n\nThe company cautioned the benchmark evaluated computational performance only and did not establish clinical validity or predictive value of any gene combinations; Quantum X plans to progress toward larger datasets and eventual execution on quantum hardware.","key_figures":{"customDimensions":{"benchmark_hardware":"AWS g4dn.16xlarge with NVIDIA T4 Tensor Core GPU, IBM Qiskit Aer simulation","cpu_analysis_hours":"~8.4","gpu_analysis_hours":"~0.5","patients_in_dataset":11,"gpu_acceleration_factor":"~16.8x","gene_expression_features":3531,"three_gene_combinations_searched":7331162245,"correlated_gene_triplets_identified":"~22.2 million"}},"named_entities":{"people":[{"name":"Dr. Tidhar Turgeman","role":"Head of clinical trials data analysis"},{"name":"Michal Efraty","role":"Investor Relations"}],"products":["GPU-accelerated quantum-simulation platform","CliniQuantum","NVIDIA T4 Tensor Core GPU","IBM Qiskit Aer"],"companies":[{"name":"Quantum X Labs Inc.","ticker":"QXL","relationship":"filer"},{"name":"CliniQuantum","relationship":"subsidiary"},{"name":"Gix Media","relationship":"subsidiary"},{"name":"Metagramm","relationship":"subsidiary"},{"name":"NVIDIA","ticker":"NVDA","relationship":"hardware supplier"},{"name":"Amazon Web Services","relationship":"cloud infrastructure provider"},{"name":"IBM","ticker":"IBM","relationship":"quantum simulation software (Qiskit Aer)"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-06T12:55:07.578Z","global_importance":15,"audience_relevance":12,"importance_components":{"tickerTier":"micro-cap","eventGravity":"technical benchmark, no commercial impact","issuerAuthored":true,"clinicalValidityDisclaimed":true}},"durationMs":7260,"modelName":"glm-5.3-flashx"}}